In vitro and in vivo evaluation of clinically-approved ionizable cationic lipids shows divergent results between mRNA transfection and vaccine efficacy

Escalona-Rayo, Oscar; Zeng, Ye; Knol, Renzo; Kock, Thomas; Aschmann, Dennis; Slütter, Bram; Kros, Alexander

doi:10.1016/j.biopha.2023.115065

Cited by 5 publications

(2 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The chemical identity of the ionizable lipid has also been seen to impact the biodistribution profile of lipid nanoparticles. 36–40 Escalona-Rayo et al demonstrated in vivo biodistribution of DiD-labeled lipid nanoparticles containing clinically approved ionizable cationic lipids (MC3, SM-102, and ALC-0315). They discovered that 24 hours after injection, these lipid nanoparticles had accumulated in endothelial cells and the extravascular space throughout the zebrafish embryo body.…”

Section: Lipid Nanoparticles: Components Formulation and Mrna Deliver...mentioning

confidence: 99%

“…Notably, ALC-0315-based lipid nanoparticles accumulated the most in the extravascular space. 36 Lam et al compared intramuscular administration of firefly luciferase mRNA encapsulated in lipid nanoparticles containing lipid benchmarks (MC3, SM-102, and ALC-0315), in mice. Six hours post-injection, ALC-0315 and SM-102 nanoparticles provided comparable luciferase expression levels at the injection site, which outperformed those observed with MC3 lipids.…”

Section: Lipid Nanoparticles: Components Formulation and Mrna Deliver...mentioning

confidence: 99%

See 1 more Smart Citation

Advances in lipid nanoparticle mRNA therapeutics beyond COVID-19 vaccines

Wu,

Yu,

de Lázaro

2024

Nanoscale

View full text Add to dashboard Cite

show abstract

Section: Lipid Nanoparticles: Components Formulation and Mrna Deliver...mentioning

confidence: 99%

Section: Lipid Nanoparticles: Components Formulation and Mrna Deliver...mentioning

confidence: 99%

Advances in lipid nanoparticle mRNA therapeutics beyond COVID-19 vaccines

Wu,

Yu,

de Lázaro

2024

Nanoscale

View full text Add to dashboard Cite

show abstract

Lipid nanoparticles-based RNA therapies for breast cancer treatment

Serpico,

Zhu,

Maia

et al. 2024

Drug Deliv. and Transl. Res.

View full text Add to dashboard Cite

Breast cancer (BC) prevails as a major burden on global healthcare, being the most prevalent form of cancer among women. BC is a complex and heterogeneous disease, and current therapies, such as chemotherapy and radiotherapy, frequently fall short in providing effective solutions. These treatments fail to mitigate the risk of cancer recurrence and cause severe side effects that, in turn, compromise therapeutic responses in patients. Over the last decade, several strategies have been proposed to overcome these limitations. Among them, RNA-based technologies have demonstrated their potential across various clinical applications, notably in cancer therapy. However, RNA therapies are still limited by a series of critical issues like off-target effect and poor stability in circulation. Thus, novel approaches have been investigated to improve the targeting and bioavailability of RNA-based formulations to achieve an appropriate therapeutic outcome. Lipid nanoparticles (LNPs) have been largely proven to be an advantageous carrier for nucleic acids and RNA. This perspective explores the most recent advances on RNA-based technology with an emphasis on LNPs’ utilization as effective nanocarriers in BC therapy and most recent progresses in their clinical applications. Graphical Abstract

show abstract